Roche Collaborates With Santaris For Development Of RNA Drugs
This article was originally published in PharmAsia News
Executive Summary
Roche returns to the RNA space after its first attempt three years ago, and this time it plans to use Santaris’ locked nucleic acid (LNA) platform for overcoming delivery difficulties.